RxDoctor Payments Data

Jairaj Mulchandani, MD

Internal Medicine · Wayne, MINPI 1174698724

Payments from drug & device makers

$541in general payments, 2019–2025

Across 33 payments — averaging $16.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$217
  • E.r. Squibb & Sons, L.L.C.$135
  • Lilly USA, LLC$41
  • AstraZeneca$34
  • AbbVie$29
  • Boehringer Ingelheim$29
  • plus $57 from 3 others

What the payments were for

  • Food & beverage$541100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK13$217
E.r. Squibb & Sons, L.L.C.10$135
Lilly USA, LLC2$41
AstraZeneca2$34
AbbVie1$29
Boehringer Ingelheim2$29
Pfizer1$20
Novartis1$20
Circassia Inc.1$17

How this compares

$541 in reported general payments places this provider in the 65th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$33,230
Medicare patients
57
Services billed
451

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban66$66,625
Trelegy ElliptaFluticasone/Umeclidin/Vilanter51$59,989
JanuviaSitagliptin Phosphate38$47,352
JardianceEmpagliflozin18$25,770
Breo ElliptaFluticasone/Vilanterol11$4,421
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$3,348
Atorvastatin Calcium200$2,518
Albuterol Sulfate HfaAlbuterol Sulfate41$1,887
Potassium Chloride66$1,743
Metoprolol Succinate78$1,624
Ventolin HfaAlbuterol Sulfate20$1,586
Amlodipine Besylate132$1,447
Tolterodine Tartrate ErTolterodine Tartrate16$1,263
Pantoprazole Sodium96$1,229
Nano 2nd Gen Pen NeedlePen Needle, Diabetic13$1,193

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$20$66,62566 claims
GSKTrelegy Ellipta, Breo Ellipta$217$64,41062 claims
Boehringer IngelheimJardiance$29$25,77018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Wayne

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →